These regional webinars will focus on optimizing eye-related side effect management and patient counselling for patients receiving treatment for relapsed/refractory multiple myeloma with antibody-drug conjugates (ADCs). 

During the webinar we will:

Share real-life insights on factors that contribute to treatment decision-making when initiating new myeloma therapies.

Apply practical considerations related to dosing and administration of novel anti-BCMA therapies, including antibody-drug conjugates (ADCs), to support evidence-based, patient-centred treatment managment

Demonstrate how to streamline collaboration with other healthcare professionals, with a focus on adverse event management